This mode of action is observed in MLL-fusion models but LSD1 inhibitors are much less active (μM range) in non-MLL cell models, even those over-expressing HOXA9, such as the U937 AML cell model (CALM-AF10 fusion). The gene discussed is KMT2A; the disease is acute myeloid leukemia.